Lysanne Campeau

List of Publications by Year
in descending order

57	1,077	430442	454577
papers	citations	18 h-index	30 g-index

58	58	58	1427
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Modulation of diabetic kidney disease markers by an antagonist of p75NTR in streptozotocin-treated mice. Gene, 2022, 838, 146729.	1.0	2
2	Imbalance of nerve growth factor metabolism in aging women with overactive bladder syndrome. World Journal of Urology, 2021, 39, 2055-2063.	1.2	11
3	Multicentered Assessment of Clinical Outcomes and Factors Associated With Failure of the Adjustable TransObturator Male System (ATOMS). Urology, 2021, 148, 280-286.	0.5	10
4	Receptor GPR91 contributes to voiding function and detrusor relaxation mediated by succinate. Neurourology and Urodynamics, 2021, 40, 120-130.	0.8	3
5	Deleterious impact of nerve growth factor precursor (proNGF) on bladder urothelial and smooth muscle cells. Cellular Signalling, 2021, 81, 109936.	1.7	6
6	Adaptation to partial urethral obstruction in healthy aging LOU rats and the role of nerve growth factor signaling pathway in the bladder. Experimental Gerontology, 2021, , 111625.	1.2	0
7	Osr1 Is Required for Mesenchymal Derivatives That Produce Collagen in the Bladder. International Journal of Molecular Sciences, 2021, 22, 12387.	1.8	2
8	Urinary metabolomics predict the severity of overactive bladder syndrome in an aging female population. International Urogynecology Journal, 2020, 31, 1023-1031.	0.7	10
9	Antagonism of proNGF or its receptor p75NTR reverses remodelling and improves bladder function in a mouse model of diabetic voiding dysfunction. Diabetologia, 2020, 63, 1932-1946.	2.9	11
10	Are Beta 3 Adrenergic Agonists Now the Preferred Pharmacologic Management of Overactive Bladder?. Current Urology Reports, 2020, 21, 49.	1.0	10
11	Canadian Urological Association Best Practice Report: Catheter use. Canadian Urological Association Journal, 2020, 14, E281-E289.	0.3	12
12	Best practices for cystometric evaluation of lower urinary tract function in muriform rodents. Neurourology and Urodynamics, 2020, 39, 1868-1884.	0.8	22
13	What do we really know about the role of caffeine on urinary tract symptoms? A scoping review on caffeine consumption and lower urinary tract symptoms in adults. Neurourology and Urodynamics, 2020, 39, 1217-1233.	0.8	8
14	Shortâ€term evaluation of the adjustable bulbourethral male sling for postâ€prostatectomy urinary incontinence. LUTS: Lower Urinary Tract Symptoms, 2019, 11, O111-O116.	0.6	2
15	Pharmacokinetic and Pharmacodynamic Properties of a Micro-Dose Nasal Spray Formulation of Desmopressin (AV002) in Healthy Water-Loaded Subjects. Pharmaceutical Research, 2019, 36, 92.	1.7	7
16	Bladder overdistension with polyuria in a hypertensive rat model. Neurourology and Urodynamics, 2018, 37, 1904-1912.	0.8	8
17	A costâ€utility analysis of artificial urinary sphincter versus AdVance male sling in post prostatectomy stress urinary incontinence: A publicly funded health care perspective. Neurourology and Urodynamics, 2018, 37, 2195-2203.	0.8	6
18	Lumbar to sacral root rerouting to restore bladder function in a feline spinal cord injury model: Urodynamic and retrograde nerve tracing results from a pilot study. Neurourology and Urodynamics, 2018, 37, 153-162.	0.8	9

#	Article	IF	Citations
19	Radiation Exposure During Videourodynamics: Establishing Risk Factors. LUTS: Lower Urinary Tract Symptoms, 2018, 10, 181-185.	0.6	3
20	Canadian Urological Association guideline: Diagnosis, management, and surveillance of neurogenic lower urinary tract dysfunction â€“ Executive summary. Canadian Urological Association Journal, 2018, 13, 156-165.	0.3	11
21	Canadian Urological Association guideline: Diagnosis, management, and surveillance of neurogenic lower urinary tract dysfunction - Full text. Canadian Urological Association Journal, 2018, 13, E157-E176.	0.3	29
22	How long do we have to treat overactive bladder syndrome? A questionnaire survey of Canadian urologists and gynecologists. Canadian Urological Association Journal, 2018, 12, E378-83.	0.3	4
23	Succinate decreases bladder function in a rat model associated with metabolic syndrome. Neurourology and Urodynamics, 2018, 37, 1549-1558.	0.8	9
24	Beta-3 Adrenoceptor Signaling Pathways in Urothelial and Smooth Muscle Cells in the Presence of Succinate. Journal of Pharmacology and Experimental Therapeutics, 2018, 367, 252-259.	1.3	11
25	Teaching and evaluation of basic urodynamic skills in urology residency programs: Randomized controlled study. Neurourology and Urodynamics, 2018, 37, 2724-2731.	0.8	7
26	We should not use oxybutynin chloride in OAB. Neurourology and Urodynamics, 2017, 36, 822-823.	0.8	2
27	Succinate, increased in metabolic syndrome, activates GPR91 receptor signaling in urothelial cells. Cellular Signalling, 2017, 37, 31-39.	1.7	20
28	Best practice policy statement on urodynamic antibiotic prophylaxis in the nonâ€index patient. Neurourology and Urodynamics, 2017, 36, 915-926.	0.8	31
29	CUA guideline on adult overactive bladder. Canadian Urological Association Journal, 2017, 11, 142.	0.3	105
30	Stress urinary incontinence in women: Current and emerging therapeutic options. Canadian Urological Association Journal, 2017, 11, 155.	0.3	8
31	Early Fesoterodine Fumarate Administration Prevents Neurogenic Detrusor Overactivity in a Spinal Cord Transected Rat Model. PLoS ONE, 2017, 12, e0169694.	1.1	6
32	Appendix: Executive summary of CUA guideline on adult overactive bladder. Canadian Urological Association Journal, 2017, 11, 248.	0.3	1
33	Prospective evaluation of anxiety, pain, and embarrassment associated with cystoscopy and urodynamic testing in clinical practice. Canadian Urological Association Journal, 2017, 11, 104.	0.3	45
34	Montreal electronic artificial urinary sphincters: Our futuristic alternatives to the AMS800â„¢. Canadian Urological Association Journal, 2017, 11, E396-404.	0.3	15
35	Bone Marrow Mesenchymal Stem Cell Therapy for Voiding Dysfunction. Current Urology Reports, 2015, 16, 49.	1.0	9
36	Bladder function in a cannabinoid receptor type 1 knockout mouse. BJU International, 2014, 113, 144-151.	1.3	13

#	Article	IF	Citations
37	Characterization of bladder function in a cannabinoid receptor type 2 knockout mouse in vivo and in vitro. Neurourology and Urodynamics, 2014, 33, 566-570.	0.8	7
38	Effects of Allogeneic Bone Marrow Derived Mesenchymal Stromal Cell Therapy on Voiding Function in a Rat Model of Parkinson Disease. Journal of Urology, 2014, 191, 850-859.	0.2	20
39	Urodynamics in Stress Incontinence. Urologic Clinics of North America, 2014, 41, 393-398.	0.8	3
40	Effect of melatonin on chronic bladderâ€ischaemiaâ€associated changes in rat bladder function. BJU International, 2013, 112, E221-30.	1.3	25
41	Lack of nicotinamide mononucleotide adenylyltransferase 2 (<scp>N</scp>mnat2): Consequences for mouse bladder development and function. Neurourology and Urodynamics, 2013, 32, 1130-1136.	0.8	2
42	Stem Cell Therapy Ameliorates Bladder Dysfunction in an Animal Model of Parkinson Disease. Journal of Urology, 2012, 187, 1491-1497.	0.2	48
43	Synthetic Mesh in the Surgical Repair of Pelvic Organ Prolapse: Current Status and Future Directions. Urology, 2012, 80, 237-243.	0.5	32
44	Effect of the anticonvulsant medications Pregabalin and Lamotrigine on urodynamic parameters in an animal model of neurogenic detrusor overactivity. Neurourology and Urodynamics, 2012, 31, 1197-1202.	0.8	17
45	What are the causes and consequences of bladder overdistension?: ICIâ€RS 2011. Neurourology and Urodynamics, 2012, 31, 317-321.	0.8	75
46	Normal lower urinary tract assessment in women: I. Uroflowmetry and post-void residual, pad tests, and bladder diaries. International Urogynecology Journal, 2012, 23, 681-685.	0.7	29
47	Normal urodynamic parameters in women. International Urogynecology Journal, 2012, 23, 269-277.	0.7	46
48	Pelvic floor disorders: linking genetic risk factors to biochemical changes. BJU International, 2011, 108, 1240-1247.	1.3	66
49	Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. British Journal of Clinical Pharmacology, 2011, 72, 186-196.	1.1	56
50	Bladder Dysfunction and Parkinsonism: Current Pathophysiological Understanding and Management Strategies. Current Urology Reports, 2011, 12, 396-403.	1.0	24
51	Bone marrow mesenchymal stromal cell therapy for external urethral sphincter restoration in a rat model of stress urinary incontinence. Neurourology and Urodynamics, 2011, 30, 447-455.	0.8	78
52	Male stress urinary incontinence: assessing patient-reported outcomes. Canadian Urological Association Journal, 2011, 5, 273-273.	0.3	1
53	Urodynamic parameters evolution after artificial urinary sphincter implantation for post-radical prostatectomy incontinence with concomitant bladder dysfunction. Canadian Journal of Urology, 2011, 18, 5695-8.	0.0	19
54	Indwelling catheters and neurogenic bladder: Are they really that bad?. Current Bladder Dysfunction Reports, 2009, 4, 132-136.	0.2	0

#	Article	IF	Citations
55	Urethral bulking agents: Techniques and outcomes. Current Urology Reports, 2009, 10, 396-400.	1.0	47
56	Effect of Antiepileptic Agent, Levetiracetam, on Urodynamic Parameters and Neurogenic Bladder Overactivity in Chronically Paraplegic Rats. Urology, 2009, 73, 922-927.	0.5	6
57	Evaluation and management of urinary retention after a suburethral sling procedure in women. Current Urology Reports, 2008, 9, 412-418.	1.0	8